Yanoyan, Esperita B.
HRN: 21-87-51 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/06/2022
CO-AMOXICLAV 625MG (TAB)
09/06/2022
09/13/2022
PO
625mg
TID
CAP MR
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes